Combinations May Be the Future in HCC
Insights From: Richard Finn, MD, David Geffen School of Medicine at UCLA
Novel studies looking at combining locoregional therapies with newer immuno-oncology agents for early-stage hepatocellular carcinoma (HCC).
Evolving the treatment landscape of hepatocellular carcinoma (HCC) by moving effective systemic therapy combinations into the frontline.
Improving overall survival in patients with advanced or metastatic hepatocellular carcinoma by combining immunotherapies with tyrosine kinase inhibitors (TKIs) or novel antibodies.